Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergy AND Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: Allergy AND Asthma. Displaying page 4 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000823-16 Sponsor Protocol Number: AL0703st Start Date*: 2007-11-20
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicenter, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual specific immunotherapy in patielnts with rhinoconjunctivi...
    Medical condition: IgE-mediated allergic disease manifested as symptoms of allergic rhinoconjunctivitis with or without controlled asthma caused by grass pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048908 Seasonal allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002567-99 Sponsor Protocol Number: GRC17536-202 Start Date*: 2012-10-01
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: An integrated Phase I/IIa study to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled GRC 17536 in healthy adult volunteers and multiple ascending doses in ...
    Medical condition: Respiratory conditions such as mild asthma.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003000-35 Sponsor Protocol Number: Final Version 1.0 Hyposensitisation Start Date*: 2007-07-09
    Sponsor Name:Department of Occupational and Environmental Dermatology, Malmö University Hospital
    Full Title: A randomized controlled single blind multicenter study to investigate the induction of aluminium contact allergy in children/adults receiving hyposensitisation therapy due to allergic disease. Chi...
    Medical condition: The development of contact allergy to aluminium during hyposensitization therapy.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003142-34 Sponsor Protocol Number: 2005-061 Start Date*: 2005-09-20
    Sponsor Name:Respiratory and Allergy Research Unit
    Full Title: Elite sport and development of asthma: Airway inflammation and treatment.
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011504-36 Sponsor Protocol Number: AL0906rP Start Date*: 2010-02-02
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma
    Medical condition: ICD classification code: J45.0 and J 30.1 Rhiniconjunctivitis +/- asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PL (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005048-17 Sponsor Protocol Number: VRP080415 Start Date*: 2009-01-27
    Sponsor Name:Verona Pharma Plc
    Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics
    Medical condition: Allergic Asthma and Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002771-40 Sponsor Protocol Number: PIX-01 Start Date*: 2006-08-28
    Sponsor Name:S.G.O. Johansson, MD PhD Professor
    Full Title: Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair. A pilot study.
    Medical condition: Allergic asthma and or rhinitis due to allergy to cat dander
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005550-30 Sponsor Protocol Number: SB/0042 Start Date*: 2014-06-10
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinit...
    Medical condition: Moderate to severe birch pollen induced allergic rhinitis/rhinoconjunctivitis with or without mild to moderate persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005388-30 Sponsor Protocol Number: T525-STD-043 Start Date*: 2022-11-21
    Sponsor Name:Inmunotek, S.L.
    Full Title: Quercus ilex and Quercus robur allergenic extracts. Determination of the in vivo allergenic potency in histamine equivalent units (HEP).
    Medical condition: Allergy to Quercus ilex and Quercus robur pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005389-32 Sponsor Protocol Number: T521-STD-044 Start Date*: 2023-03-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: Juniperus oxycedrus and Cupressus arizonica allergen extracts. Determination of the in vivo allergenic potency in histamine equivalent units (HEP).
    Medical condition: Allergy to Cupressaceae: Juniperus oxycedrus and Cupressus arizonica
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-001699-12 Sponsor Protocol Number: 6078-PG-PSC-193 Start Date*: 2012-10-18
    Sponsor Name:Laboratorios LETI, S.L.U
    Full Title: Prospective, open uncontrolled study to evaluate the safety of Depigoid with two pollen combinations ( Grasses/Olea and Grasses/ Parietaria) 2000 DPP/ml in patients with allergic rhinitis or rhinoc...
    Medical condition: Allergic rhinitis or rhinojunctivitis, with or without seasonal asthma to more than one of the following pollens: Grasses, Olea europaea and Parietaria judaica.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007657-12 Sponsor Protocol Number: ParLais/09 Start Date*: 2009-10-26
    Sponsor Name:LOFARMA
    Full Title: Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)adminis...
    Medical condition: Subjects with Parietaria pollen allergy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000870-79 Sponsor Protocol Number: 101-PG-PSC-186 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios LETI, S.L.U.
    Full Title: Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in pa...
    Medical condition: Allergic rhinitis or rhinoconjunctivitis with or without mild persistent or intermittent asthma, to Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002047-18 Sponsor Protocol Number: SM/0044 Start Date*: 2015-01-14
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis ...
    Medical condition: Patients, 18-60 years of age, suffering from house dust mites-induced persistent allergic rhinitis/rhinoconjunctivitis with or without concomitant at least partly controlled asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014923-22 Sponsor Protocol Number: GT-23 Start Date*: 2009-11-27
    Sponsor Name:ALK-ABELLO`
    Full Title: A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled con...
    Medical condition: children from 5 to 18 years with grass pollen induced rhinoconjunctivitis with/without controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054928 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004638-40 Sponsor Protocol Number: D3250C00025 Start Date*: 2020-02-14
    Sponsor Name:AstraZenenca AB
    Full Title: An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma.
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005471-88 Sponsor Protocol Number: MG56-SIT-012 Start Date*: 2015-11-27
    Sponsor Name:INMUNOTEK, S.L.
    Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against grass pollen allergy
    Medical condition: Grass pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005169-41 Sponsor Protocol Number: SL-372A Start Date*: 2023-03-16
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004309-28 Sponsor Protocol Number: MEU19/383 Start Date*: 2020-03-04
    Sponsor Name:The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study)
    Full Title: Application of Chronotherapy to Asthma: Towards the Personalisation of Asthma Management. A randomised, mechanistic study of 400mcg Clenil® Modulite® (Beclometasone dipropionate) in the morning ...
    Medical condition: Mild to moderate atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 21 16:54:46 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA